Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2009-017581-22-DE
EUCTR2009-017581-22-DE
Active, not recruiting
Not Applicable

Cognitive impairment in bipolar disorder treated with aripiprazole - CIBA

Department of Psychiatry and Psychotherapy, Charity University Medicine0 sitesDecember 7, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBipolar disorder is among the most severely debilitating diseases. Patients with bipolar disorder generally experience high rates of relapse, a chronic recurrent course, lingering residual symptoms, functional impairment, psychosocial disability and diminished well-being. More recent data have underlined the importance of neurocognitive impairments in the euthymic state including impairments in attention, memory and executive function.
DrugsAbilify

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bipolar disorder is among the most severely debilitating diseases. Patients with bipolar disorder generally experience high rates of relapse, a chronic recurrent course, lingering residual symptoms, functional impairment, psychosocial disability and diminished well-being. More recent data have underlined the importance of neurocognitive impairments in the euthymic state including impairments in attention, memory and executive function.
Sponsor
Department of Psychiatry and Psychotherapy, Charity University Medicine
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 7, 2010
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Department of Psychiatry and Psychotherapy, Charity University Medicine

Eligibility Criteria

Inclusion Criteria

  • •Bipolar Disorder (BP I \+ BP II)
  • •Ethymic mood state since 6 months at least
  • •Stable medication with mood stabilizers
  • •Age \> 18 y.
  • •Cognitive Impairment measured on self reporting questionnaires
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •Axis 1 condition other than bipolar disorder during last 6 month
  • •organic brain disorder
  • •pregnancy or breast feeding

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Enhancing cognition in bipolar disorderBipolar disorderMental and Behavioural Disorders
ISRCTN93360820Suffolk Mental Health Partnership NHS Trust (UK)20
Recruiting
Phase 2
Improvement of cognitive function in bipolar disorder by aripiprazole adjunct treatmentF31.7Bipolar affective disorder, currently in remission
DRKS00004316Bristol-Myers Squibb GmbH & Co. KGaA 52
Recruiting
Phase 2
Riluzole in the control of obsession in bipolar patients
IRCT20211118053093N4Shiraz University of Medical Sciences40
Recruiting
Not Applicable
Psychiatric and cognitive function in patients with Neuroendocrine tumours with carcinoid syndrome.cognitieve stoornissencognitive impairmentdepression10027946
NL-OMON45631ederlands Kanker Instituut85
Active, not recruiting
Phase 1
Enhancing cognition in bipolar disorder - Enhancing cognition in bipolar disorder
EUCTR2004-005010-37-GBSuffolk Mental Health Partnerships Trust20